Ten years of treatment with tibolone 2.5 mg daily: Effects on bone loss in postmenopausal women

Climacteric

Volumn 5, Issue 4, 2002, Pages 390-398

  Rymer, J ^a,b   Robinson, J ^a   Fogelman, I ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bone loss; Hormone replacement therapy; Long term; Postmenopausal; Tibolone

Indexed keywords

TIBOLONE;

ACNE; ADULT; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; EDEMA; ENDOMETRIUM CANCER; FEMALE; FEMUR NECK; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIRSUTISM; HOT FLUSH; HUMAN; HYPERTENSION; LONG TERM CARE; LOW BACK PAIN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MIGRAINE; OSTEOLYSIS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RASH; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CYTOLOGY; VAGINITIS; WEIGHT GAIN;

EID: 0036970056     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.5.4.390.398     Document Type: Article

References (34)

1. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8
2. Ederveen AGH, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. J Bone Miner Res 2001;16:1651-7
3. Markiewicz L, Gurpride E. In vitro evaluation of estrogenic, estrogen antagonistic and progestogenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535-41
4. Völker W, Coelingh Bennink HJT, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203-8
5. Hammar M, Christau S, Nathorst-Boöös J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-11
6. Morris EP, Wilson PO, Robinson J, Rymer JM. Long-term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999;106:954-9
7. Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854-7
8. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas 1992;15:151-8
9. Gompel A, Kandouz M, Siromachkova M, et al. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;11(Suppl 1):77-9
10. Lippert C, Seeger H, Wallwiener D, Mueck AO. Tibolone versus 17β-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur J Gynaecol Oncol 2002;23:127-30
11. Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial) over 8 years. Maturitas 1995;21:71-6
12. Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
13. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporos Int 1994;4:314-19
14. Rymer J, Robinson J, Fogelman I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int 2001;12:478-83
15. Chopra A. Osteoporosis: a new understanding of its impact and pathogenesis. J Am Osteopath Assoc 2000;100(Suppl):S1-S4
16. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-5
17. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33
18. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26
19. Milner M, Harrison RF, Gilligan E, Kelly A. Bone density changes during 2 years' treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Menopause 2000;7:327-33
20. Thiébaud D, Bigler JM, Renteria S, et al. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxy-progesterone acetate versus tibolone. Climacteric 1998;1:202-10
21. Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-22
22. Bjarnason NH, Bjarnason K, Hassager C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997;20:151-5
23. Geusens P, Dequeker J, Gielen J, Schot LPC. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991;13:155-62
24. Studd J, Arnala I, Kicovic PM, Zamblera D, Kröger H, Holland N. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998;92:574-9
25. Egarter C, Sator M, Berghammer P, Huber J. Efficacy, tolerability and rare side effects of tibolone treatment in postmenopausal women. Int J Gynecol Obstet 1999;64:281-6
26. Rymer J, Chapman MG, Fogelman I. A study of the effect of tibolone on the vagina in postmenopausal women. Maturitas 1994;18:127-33
27. Gompel A, Siromachkova M, Lombet A, Kloosterboer HJ, Rostene W. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36(Suppl 4):S76-7
28. Dören M, Rübig A, Coelingh Bennink HJT, Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299-306
29. Huber J, Palacios S, Berglund L, et al. The effect of tibolone compared with conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-93
30. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. Clin Drug Invest 2000;20:101-7
31. Colacurci N, Fornaro F, de Franciscis P, Palermo M, del Vecchio E. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-64
32. Erel CT, Esen G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-7
33. Tax L, Goorissen EM, Kicovic PM. Clinical profile of Org OD14. Maturitas 1987;Suppl 1:3-13
34. Genazzani AR, Petraglia F, Facchinetti F, et al. Effects of Org OD14 on pituitary and peripheral β-endorphin in castrated rats and in postmenopausal women. Maturitas 1987;Suppl 1:35-48